CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Kura Oncology, Inc.

KURA
$978MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for KURA. That does not mean none is planned.

Get an email about KURA's next catalysts

Track Kura Oncology (KURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

0 upcoming, 1 past

No catalysts found.

How KURA's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaSAN DIEGO192 employees
Drug Pipeline

Frequently asked questions

What is in Kura Oncology, Inc.'s drug pipeline?β†’

CatalystAlert tracks 5 drug candidates in Kura Oncology, Inc.'s (KURA) pipeline across Phase 3, Phase 2. Its lead program is Cytarabine (Ara-C) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Kura Oncology, Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Kura Oncology, Inc. (KURA) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track KURA biotech catalysts?β†’

Add KURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kura Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply